To say that there’s a lot happening in our industry—and the world—in 2025 is a vast understatement. The market has seen some tectonic shifts over the past year, from regulatory changes to political influences to major market uncertainty. Questions abound, but most pharma leaders are asking themselves the same thing: What will this market evolution mean for manufacturers and, ultimately, the patients?
Earlier this year, we conducted our annual State of Patient Access survey to better understand the current state of the industry. We gathered insights from 250 high-level stakeholders across pharma to explore how they’re weathering the winds of change. Here, authors Steve Callahan and Hannah Baxter share their key perspectives on what it all means, and how pharma companies can leverage this insight to power commercial decision-making.
RESEARCH REPORT
The 2025 State of Patient Access
Authors Steve Callahan, Hannah Baxter and Izabela Chmielewska take a deep dive into the survey results to better understand today’s evolving market access landscape.
EXECUTIVE SUMMARY
Maximizing Access Strategies in the Era of Biosimilars
Explore the most compelling survey findings—and key expert insights—in this Biopharma Dive Executive Summary.
WEBINAR
How to Overcome Market Access Challenges in the Era of Biosimilars
In this webinar, hosted by Biopharma Dive, the authors explore key insights from the survey and how brands are rethinking their strategies in response to market changes.
ARTICLE
Patient Access Barriers in 2025 and Beyond
In this blog, authors Steve Callahan and Hannah Baxter discuss the most compelling findings from our industry survey—and how they might affect market access planning for years to come.
INFOGRAPHIC
The Future of Biosimilar Development
Learn which market factors are spurring manufacturers to invest in new biosimilar development.
